Ravi A. Madan

9.9k total citations · 1 hit paper
286 papers, 6.7k citations indexed

About

Ravi A. Madan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Ravi A. Madan has authored 286 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Oncology, 164 papers in Pulmonary and Respiratory Medicine and 133 papers in Immunology. Recurrent topics in Ravi A. Madan's work include Prostate Cancer Treatment and Research (154 papers), Cancer Immunotherapy and Biomarkers (135 papers) and Immunotherapy and Immune Responses (124 papers). Ravi A. Madan is often cited by papers focused on Prostate Cancer Treatment and Research (154 papers), Cancer Immunotherapy and Biomarkers (135 papers) and Immunotherapy and Immune Responses (124 papers). Ravi A. Madan collaborates with scholars based in United States, Germany and Spain. Ravi A. Madan's co-authors include James L. Gulley, Jeffrey Schlom, William L. Dahut, Philip M. Arlen, Christopher R. Heery, Marijo Bilušić, Renee N. Donahue, Seth M. Steinberg, Jennifer L. Marté and Caroline Jochéms and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ravi A. Madan

275 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

2018 327 citations Julius Strauss, Christopher R. Heery et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Ravi A. Madan

Since Specialization

Citations

This map shows the geographic impact of Ravi A. Madan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravi A. Madan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravi A. Madan more than expected).

Fields of papers citing papers by Ravi A. Madan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ravi A. Madan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravi A. Madan. The network helps show where Ravi A. Madan may publish in the future.

Co-authorship network of co-authors of Ravi A. Madan

This figure shows the co-authorship network connecting the top 25 collaborators of Ravi A. Madan. A scholar is included among the top collaborators of Ravi A. Madan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravi A. Madan. Ravi A. Madan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Relugolix in Clinical Practice: The Best Route for All? 2023 ·The Oncologist ·Lisa M. Cordes, Fatima Karzai, William D. Figg, Ravi A. Madan	6
2	Emerging treatment options for prostate cancer 2023 ·Expert Review of Anticancer Therapy ·Mohammad Atiq, (unknown), Fatima Karzai, Ravi A. Madan, Jeanny B. Aragon‐Ching	8
3	A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors 2023 ·The Oncologist ·Margaret E. Gatti‐Mays, Nicholas Tschernia, Julius Strauss, Ravi A. Madan, Fatima Karzai, Marijo Bilušić, Jason M. Redman, Houssein Abdul Sater, Charalampos S. Floudas, (unknown), Renee N. Donahue, Caroline Jochéms, Jennifer L. Marté, (unknown), Sheri McMahon, Elizabeth Lamping, Lisa M. Cordes, Jeffrey Schlom, James L. Gulley	9
4	The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer 2022 ·Cancers ·(unknown), Winston Tan, John A. Copland, (unknown), Ephraim E. Parent, Ravi A. Madan	7
5	Disparities in Cancer Care and the Asian American Population 2021 ·The Oncologist ·Richard J. Lee, Ravi A. Madan, Jayoung Kim, Edwin M. Posadas, Evan Y. Yu	84
6	Protein kinase inhibitors for the treatment of prostate cancer 2021 ·Expert Opinion on Pharmacotherapy ·Vincent Chau, Ravi A. Madan, Jeanny B. Aragon‐Ching	9
7	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) 2021 ·Journal for ImmunoTherapy of Cancer ·Marijo Bilušić, Sheri McMahon, Ravi A. Madan, Fatima Karzai, (unknown), Renee N. Donahue, Claudia Palena, Caroline Jochéms, Jennifer L. Marté, Charalampos S. Floudas, Julius Strauss, Jason M. Redman, Houssein Abdul Sater, Shahrooz Rabizadeh, Patrick Soon‐Shiong, Jeffrey Schlom, James L. Gulley	43
8	The Immunotherapy Revolution in Genitourinary Malignancies 2020 ·Immunotherapy ·Shruti U. Gandhy, Ravi A. Madan, Jeanny B. Aragon‐Ching	9
9	A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules 2019 ·Clinical Cancer Research ·Margaret E. Gatti‐Mays, Julius Strauss, Renee N. Donahue, Claudia Palena, Jaydira Del Rivero, Jason M. Redman, Ravi A. Madan, Jennifer L. Marté, Lisa M. Cordes, Elizabeth Lamping, (unknown), (unknown), Eva Wagner, (unknown), Christopher R. Heery, Jeffrey Schlom, James L. Gulley	45
10	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management 2019 ·The Oncologist ·Jaydira Del Rivero, Lisa M. Cordes, Joanna Kłubo-Gwieździńska, Ravi A. Madan, Lynnette K. Nieman, James L. Gulley	58
11	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors 2018 ·Clinical Cancer Research ·Julius Strauss, Christopher R. Heery, Joseph W. Kim, Caroline Jochéms, Renee N. Donahue, (unknown), Sheri McMahon, Elizabeth Lamping, Jennifer L. Marté, Ravi A. Madan, Marijo Bilušić, Matthew R. Silver, (unknown), Jeffrey Schlom, James L. Gulley	116
12	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors breakdown → 2018 ·Clinical Cancer Research ·Julius Strauss, Christopher R. Heery, Jeffrey Schlom, Ravi A. Madan, Liang Cao, Zhigang Kang, Elizabeth Lamping, Jennifer L. Marté, Renee N. Donahue, Italia Grenga, Lisa M. Cordes, Olaf Christensen, Lisa Mahnke, Christoph Helwig, James L. Gulley	327
13	Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury 2017 ·Clinical Cancer Research ·Christopher R. Heery, Claudia Palena, Sheri McMahon, Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Ulrike Dirmeier, Lisa M. Cordes, (unknown), William L. Dahut, Harpreet Singh, Ravi A. Madan, Romaine I. Fernando, Duane H. Hamilton, Jeffrey Schlom, James L. Gulley	51
14	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types 2016 ·Lauren M. Lepone, Renee N. Donahue, Italia Grenga, Simon Metenou, Jacob Richards, Christopher R. Heery, Ravi A. Madan, James L. Gulley, Jeffrey Schlom	3
15	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy 2016 ·Cancer Immunology Research ·Benedetto Farsaci, Renee N. Donahue, Italia Grenga, Lauren M. Lepone, Peter Kim, (unknown), Janet Siebert, Nuhad K. Ibrahim, Ravi A. Madan, Christopher R. Heery, James L. Gulley, Jeffrey Schlom	26
16	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury 2015 ·Cancer Immunology Research ·Christopher R. Heery, (unknown), Myrna Rauckhorst, Jennifer L. Marté, Renee N. Donahue, Italia Grenga, Timothy C. Rodell, William L. Dahut, Philip M. Arlen, Ravi A. Madan, Jeffrey Schlom, James L. Gulley	104
17	Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer 2013 ·Cancer Immunology Research ·James L. Gulley, Ravi A. Madan, Kwong Y. Tsang, Caroline Jochéms, Jennifer L. Marté, Benedetto Farsaci, Jo A. Tucker, James W. Hodge, David J. Liewehr, Seth M. Steinberg, Christopher R. Heery, Jeffrey Schlom	101
18	A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer 2011 ·Clinical Cancer Research ·Mahsa Mohebtash, Kwong-Yok Tsang, Ravi A. Madan, Ngar‐Yee Huen, Diane J. Poole, Caroline Jochéms, Jacquin Jones, (unknown), Christopher R. Heery, Philip M. Arlen, Seth M. Steinberg, Mary Pazdur, Myrna Rauckhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlom, James L. Gulley	101
19	Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy 2010 ·Clinical Cancer Research ·Wilfred D. Stein, James L. Gulley, Jeff Schlom, Ravi A. Madan, William L. Dahut, William D. Figg, Yang‐Min Ning, (unknown), (unknown), Susan E. Bates, Tito Fojo	201
20	Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy 2008 ·Clinical Cancer Research ·Ravi A. Madan, James L. Gulley, Jeffrey Schlom, Seth M. Steinberg, David J. Liewehr, William L. Dahut, Philip M. Arlen	119

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact